The Development and validation of few UV Spectrophotometric methods for the determination of Apremilast in bulk form and pharmaceutical dosage form

  • Sumanta Mondal Department of pharmaceutical analysis & quality assurance, GITAM institute of pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, India
  • Sowmya Paidipati Department of pharmaceutical analysis & quality assurance, GITAM institute of pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, India
  • Sneha Potlapally Department of pharmaceutical analysis & quality assurance, GITAM institute of pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, India
  • Goutham Kumar Vanapalli Department of pharmaceutical analysis & quality assurance, GITAM institute of pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, India

Abstract

Apremilast is an analog of thalidomide and used as a medication for the treatment of certain type of psoriasis and psoriatic arthritis. It is pale yellow to white colour powder which is non-hygroscopic and practically insoluble in water and buffer solutions of wide pH range, but is soluble is lipophilic solvents like acetone , acetonitrile , butanone , dichloromethane and tetrahydrofuran. Validation study was performed to develop novel, simple, precise, sensitive and accurate UV spectrophotometric method w for the estimation of Apremilast. Double beam UV-VIS spectrophotometer (UV-1800, Shimadzu, Japan) with a pair of 10mm path length matched quartz cells were used for the study. Method A(methanol), Method B(ethanol), Method C(DMSO), Method D( acetonitrile) were developed foe estimation of Apremilast by zero-order and first-order derivative. Linearity was carried out in the concentration range of 0.2-1.0µg/ml and correlation coefficients were found to be 0.999. The relative standard deviation was found to be <2%. The LOD and LOQ were found to be 0.120µg/ml and 0.7810µg/ml respectively. Hence, the methods were validated according to ICH to guidelines and can be adopted for the routine analysis of Apremilast in pure and table dosage form.


Keywords: Apremilast, UV visible spectrophotometer, zero-order, first-order derivative, ICH guidelines.

Downloads

Download data is not yet available.

Author Biographies

Sumanta Mondal, Department of pharmaceutical analysis & quality assurance, GITAM institute of pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, India

Department of pharmaceutical analysis & quality assurance, GITAM institute of pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, India

Sowmya Paidipati, Department of pharmaceutical analysis & quality assurance, GITAM institute of pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, India

Department of pharmaceutical analysis & quality assurance, GITAM institute of pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, India

Sneha Potlapally, Department of pharmaceutical analysis & quality assurance, GITAM institute of pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, India

Department of pharmaceutical analysis & quality assurance, GITAM institute of pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, India

Goutham Kumar Vanapalli, Department of pharmaceutical analysis & quality assurance, GITAM institute of pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, India

Department of pharmaceutical analysis & quality assurance, GITAM institute of pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, India

References

1. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis, Biochem Pharmacol, 2012; 83:1583-1590.
2. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. Cyclic AMP: Master regulator of innate immune cell function, Am J Respir Cell Mol Biol, 2008; 39:127-132.
3. Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase 4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis, Br J Pharmacol, 2010; 159:842-855.
4. Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, et al. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study, Arthritis Rheum 2012; 64:3156-3167.
5. Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast, Curr Med Res Opin, 2008; 24:1529-1538.
6. Wu A, Rohane P, Ng J, DeGroot B, Colgan B, Laskin OL, et al. Safety/tolerability and pharmacokinetics of multiple oral doses of apremilast in healthy male subjects, Clin Pharmacol Ther, 2012; 91:S26.
7. Hoffmann M, Kumar G, Schafer P, Cedzik D, Capone L, Fong KL, et al. Disposition, metabolism and mass balance of [(14) C] apremilast following oral administration. Xenobiotica, 2011; 41:1063-1075.
8. Wu A, Scheffler M. First-time-in-man, safety/tolerability and pharmacokinetics of ascending oral doses of Apremilast (APR) in healthy subjects (HS). J Invest Dermatol, 2011; 131:S86.
9. Siladitya B, Subhajit G, Fahad A, Saayak S, Sritoma B. UV-Visible Spectropho- tometric Method Development and Validation of Assay of Paracetamol Tablet Formulation, Journal of Analytical and Bioanalytical Techniques 2012; 3(6):1-6.
10. Mohammad A, Sudhir K, Shashank C, Vipin KA. Validated UV spectrophotometric method for estimation of domperidone for dissolution study, Der Pharmacia Lettre, 2015; 7(6):53-58.
11. Pradeep S, Vikash KC, Praveen KV, Amit KS, Vijay Kumar Y. Development and validation of uv-visible spectrophotometric method for the determination of levofloxacin in bulk and tablet formulation, International Journal of Research and Development in Pharmacy and Life Sciences, 2015; 4(1):1375-8.
12. Sumanta Mondal, Goluguri Sunil Reddy, Prasenjit Mondal, Vadlapati Sheeba Prathyusha1, Aishwarya P Nair, and Syed Tazib Rahaman. Development and Validation of Few UV Spectrophotometric Methods for the Determination of Valganciclovir in Bulk and Pharmaceutical Dosage Form Pharm Methods, 2018; 9(2):64-68.
Statistics
29 Views | 28 Downloads
How to Cite
Mondal, S., Paidipati, S., Potlapally, S., & Vanapalli, G. K. (2019). The Development and validation of few UV Spectrophotometric methods for the determination of Apremilast in bulk form and pharmaceutical dosage form. Journal of Drug Delivery and Therapeutics, 9(2-s), 429-436. https://doi.org/10.22270/jddt.v9i2-s.2737